This little troll finds the most creative ways to sound like a different person! I will give him/her/they an A+ for creativity when it comes to presenting as a mob. Nice work troll.Are reps still getting paid?
This ^It is hard to say, but the future looks very dim. The parent company is struggling, KPA has only a carve-out co-promote with a sales force that costs at least $50MM. Not good optics nor economics.
That guy needs to get a life. What a loser.Having a conversation with yourself much TG
It is hard to say, but the future looks very dim. The parent company is struggling, KPA has only a carve-out co-promote with a sales force that costs at least $50MM. Not good optics nor economics.
Define loser? I am not sure who TG is but if he got off the Titanic before it goes down sounds like a survivor. Instead, you troll badly, those smart enough to be gone. Just so you know the definition here it is.That guy needs to get a life. What a loser.
LOSER:Define loser? I am not sure who TG is but if he got off the Titanic before it goes down sounds like a survivor. Instead, you troll badly, those smart enough to be gone. Just so you know the definition here it is.
LOSER
a person or thing that loses or has lost something, especially a game or contest:
Definitely describes you not someone out of here like even leadership fled from. Keep whistling past that graveyard.
AMEN.Let's ignore the juvenile posts, get back to some business facts and attempt to weave in a bit of longer-term strategy. Current situation - insufficient profit to cover operating expenses: parent corporation in-extremis financially; zero near-term pipeline: inexperienced KPA leadership (except J. Barna for certain purposes). Future situation: one potential product (Rho-kinase inhibitor for Fuchs): unfortunately the current sales force is too large and inexperienced to provide value in a niche, specialty therapeutic area: KCL would probably be better financially to out-licence the Rho-kinase inhibitor at the end of Phase 2 to an established ophthalmology company, terminate the KPA sales force and maintain a skeleton HO staff.
Not being venomous - just realistic.
I could sell the specialty ophthalmic product. Probably not our freshly minted reps, but many of us are capable. And y’all seem to forget that Kowa Japan has much deeper pockets than our comparatively tiny payroll.Let's ignore the juvenile posts, get back to some business facts and attempt to weave in a bit of longer-term strategy. Current situation - insufficient profit to cover operating expenses: parent corporation in-extremis financially; zero near-term pipeline: inexperienced KPA leadership (except J. Barna for certain purposes). Future situation: one potential product (Rho-kinase inhibitor for Fuchs): unfortunately the current sales force is too large and inexperienced to provide value in a niche, specialty therapeutic area: KCL would probably be better financially to out-licence the Rho-kinase inhibitor at the end of Phase 2 to an established ophthalmology company, terminate the KPA sales force and maintain a skeleton HO staff.
Not being venomous - just realistic.
The U.S. division is done. You must be new here. Everyone left years ago. Turnover is 99%. No commission. No raises. The only person left is a pretty boy that does power points and smiles. Named Rusty Nolen.I could sell the specialty ophthalmic product. Probably not our freshly minted reps, but many of us are capable. And y’all seem to forget that Kowa Japan has much deeper pockets than our comparatively tiny payroll.
Not a single thing you said in this rant was true. Loser.The U.S. division is done. You must be new here. Everyone left years ago. Turnover is 99%. No commission. No raises. The only person left is a pretty boy that does power points and smiles. Named Rusty Nolen.
Okay RustyNot a single thing you said in this rant was true. Loser.